Drugs / TNG908
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05275478 | Mar 2022 → Dec 2025 | — | Tango Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG908 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275478 ↗ |
| Action | Inhibit | “TNG908, a selective PRMT5 inhibitor, will be administered orally” NCT05275478 ↗ |
| Route | Oral | “TNG908, a selective PRMT5 inhibitor, will be administered orally” NCT05275478 ↗ |
| Target | PRMT5 | “TNG908, a selective PRMT5 inhibitor, will be administered orally” NCT05275478 ↗ |